Practical synthesis of roscovitine and CR8

Organic Process Research and Development

Volumn 13, Issue 3, 2009, Pages 641-644

  Oumata, Nassima ^a   Ferandin, Yoan ^b   Meijer, Laurent ^b   Galons, Hervé ^a  

^a INSERM   (France)

^b Protein Phosphorylation and Human Disease Group   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66249136327     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/op800284k     Document Type: Article

References (16)

1. (a) Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417- 425.
2. Malumbres, M.; Barbacid, M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 2007, 17, 60-5.
3. (a) Malumbres, M.; Pevarello, P.; Barbacid, M.; Bischoff, J. R. CDK inhibitors in cancer therapy: what is next. Trends Pharmacol. Sci. 2008, 29, 16-21.
4. Sharma, P. S.; Sharma, R.; Tyagi, R. Inhibitors of cyclin dependent kinases: Useful targets for cancer treatment. Curr. Cancer Drug Targets 2008, 8, 53-75.
5. (a) Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J. Y.; De'tivaud, L.; Leclerc, S.; Meijer, L. Inhibition of cyclin-dependent kinases by purine derivatives. Eur. J. Biochem. 1994, 224, 771-786.
6. De Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S. H. Inhibition of cyclindependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518- 526.
7. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J. P. J.; Blow, J. J.; Inagaki, N.; Inagaki, M.; Delcros, J. G.; Moulinoux, J. P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 1997, 243, 527-536.
8. Chang, Y. T.; Gray, N. G.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6, 361-375.
9. (a) Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 2003, 36, 417-425.
10. Meijer, L.; Bettayeb, K.; Galons, H. Roscovitine (CYC202, Seliciclib). In Monographs on enzyme inhibitors. CDK inhibitors and their potential as anti-tumor agents; Smith, P. J., Yue, E., Eds.; CRC Press, Taylor & Francis: Boca Raton, FL, 2006; Vol. 2, Chapter 9, pp 187-226.
11. Oumata, N.; Bettayeb, K.; Ferandin, Y.; Demange, L.; Lopez-Giral, A.; Goddard, M.-L.; Myrianthopoulos, V.; Mikros, E.; Flajolet, M.; Greengard, P.; Meijer, L.; Galons, H. Roscovitine-derived, dualspecificity inhibitors of cyclin-dependent kinases (CDKs) and casein kinase 1 (CK1). J. Med. Chem. 2008, 51, 5229-5242.
12. Bettayeb, K.; Oumata, N.; Echalier, A.; Ferandin, Y.; Endicott, J.; Galons, H.; Meijer, L. CR8: A potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008, 27, 5797-807.
13. Meijer, L.; Bisagni, E.; Legrave'rend, M. Novel purine derivatives having, in particular, antiproliferative properties, and biological uses thereof. PCT WO 97/20842, 1997.
14. Kuduk, S. D.; Chang, R. K.; Ng, C.; Murphy, K. L.; Ransom, R. W.; Tang, C.; Prueksaritamont, T.; Friedinger, R. M.; Pettibone, D. J.; Bock, M. G. Bradykinin B1 antagonists: SAR studies in the 2,3- diaminopyridine series. Bioorg. Med. Chem. Lett. 2005, 15, 3925- 3929.
15. Brown, A.; Brown, L.; Brown, T. B.; Calabrese, A.; Ellis, D.; Puhalo, N.; Smith, C. R.; Wallace, O.; Watson, L. Triazole oxytocin antagonists: Identification of aryl ether replacements for a biaryl substituent. Bioorg. Med. Chem. Lett. 2008, 18, 5242-5444.
16. Horton, D. A.; Bourne, G. T.; Mark, L.; Smythe, M. L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. ReV 2003, 103, 893-930.